Piper Sandler raised the firm's price target on Alpha Tau to $8 from $5 and keeps a Neutral rating on the shares after the company reported Q1 results, including an operating loss of $13.3M, while cash ended at $80M. The past 3-6 months have been fairly eventful for Alpha Tau on the clinical and regulatory fronts, with notable headlines across each of the key indications where the company is allocating resources, the firm notes. Piper highlights the positive early results from the REGAIN feasibility trial in recurrent GBM, enrollment wrapped in the company's ReSTART trial in recurrent cSCC, and the IMPACT trial in pancreatic cancer is expanding enrollment.
